Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
QUILLICHEW ER vs ADDERALL 30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Quillichew ER contains methylphenidate, a central nervous system (CNS) stimulant. The mechanism of action in ADHD is not fully understood, but it is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their availability in the extraneuronal space.
Adderall contains mixed amphetamine salts that increase synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and promoting release from presynaptic terminals.
Attention Deficit Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
Initial 20 mg orally once daily, titrate by 10 mg weekly to maximum 60 mg/day (methylphenidate component).
Initial: 5 mg orally once or twice daily; increase by 5 mg increments weekly; usual maintenance: 20-30 mg daily in divided doses; maximum: 40 mg/day
The terminal elimination half-life of methylphenidate is approximately 3-4 hours in children and 3.5-5 hours in adults. For Quilli Chew ER, the extended-release formulation provides a prolonged absorption phase, with an effective duration of action of up to 12 hours.
Terminal elimination half-life: d-amphetamine 10-13 hours, l-amphetamine 13-15 hours; in adults (children: 6-8 hours). The longer half-life allows for once-daily dosing.
Methylphenidate is primarily metabolized by deesterification via carboxylesterase 1 (CES1) to ritalinic acid, which is pharmacologically inactive. Minor metabolism via hydroxylation and microsomal oxidation.
Primarily hepatic via CYP2D6, with minor contributions from CYP1A2, CYP2B6, and CYP3A4.
Quilli Chew ER (methylphenidate extended-release chewable tablet) is primarily eliminated via renal excretion as metabolites (60-80%) and unchanged drug (approx. 10%). Hepatic metabolism accounts for the remainder. Fecal elimination is minimal.
Approximately 30-40% of a dose is excreted unchanged in urine; the remainder is metabolized primarily by oxidative deamination and aromatic hydroxylation. Biliary/fecal elimination accounts for less than 5%.
Methylphenidate is approximately 10-33% bound to plasma proteins, primarily albumin. Binding is low and not clinically significant.
Approximately 20-25% bound to plasma proteins, mainly albumin and alpha-1-acid glycoprotein.
Volume of distribution (Vd) for methylphenidate is approximately 2-3 L/kg, indicating extensive tissue distribution. It is not highly bound to tissues.
Vd: 3-4 L/kg (approximately 210-280 L for a 70 kg adult). This indicates extensive tissue distribution and penetration into the central nervous system.
Oral bioavailability of methylphenidate is variable and low, approximately 11-52% due to extensive first-pass metabolism. Quilli Chew ER is designed to deliver a consistent extended-release profile with a bioavailability of about 20-30% relative to immediate-release formulations.
Oral immediate-release: approximately 75-100%; oral extended-release: approximately 94% relative to immediate-release. Food does not significantly affect absorption but may delay peak concentration.
No dosage adjustment recommended for GFR >30 m L/min; avoid in GFR ≤30 m L/min.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: avoid use
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use
Children ≥6 years: initial 20 mg orally once daily, titrate by 10 mg weekly to max 60 mg/day.
Children 3-5 years: initial 2.5 mg orally once daily; increase by 2.5 mg weekly; usual range 2.5-20 mg/day. Children ≥6 years: initial 5 mg once or twice daily; increase by 5 mg weekly; usual range 5-40 mg/day in divided doses
Start at 10 mg orally once daily, titrate cautiously; monitor for increased sensitivity and cardiovascular effects.
Initiate at 2.5 mg orally once or twice daily; titrate slowly; monitor for cardiovascular effects, insomnia, and weight loss
QUILLICHEW ER has a high potential for abuse and dependence. Prolonged use may lead to drug dependence. Misuse may cause sudden death or serious cardiovascular adverse events.
Amphetamines have a high potential for abuse and dependence. Misuse may cause sudden death or serious cardiovascular events.
Serious cardiovascular events: sudden death, stroke, myocardial infarction in patients with pre-existing structural cardiac abnormalities or other serious heart problems.,Blood pressure and heart rate increase; monitor closely.,Psychiatric adverse events: exacerbation of pre-existing psychosis, mania, or aggressive behavior.,Long-term suppression of growth (weight and height) in pediatric patients.,Seizures: use with caution in patients with history of seizures.,Priapism: prolonged, painful erections may occur.,Peripheral vasculopathy: Raynaud's phenomenon.
Risk of serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities,Increased blood pressure and heart rate,Psychiatric adverse events including exacerbation of pre-existing psychosis, mania, or aggressive behavior,Serotonin syndrome risk when co-administered with serotonergic drugs,Long-term suppression of growth in children,Seizure risk in patients with history of seizures,Peripheral vasculopathy including Raynaud's phenomenon,Visual disturbances due to mydriasis
Known hypersensitivity to methylphenidate or any component of the formulation.,Concurrent use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing MAOI therapy.,Glaucoma.,Motor tics or family history of Tourette's syndrome.,Severe anxiety, tension, or agitation.,Patients with history of drug abuse or dependence.
Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Known hypersensitivity to amphetamines,Agitated states,History of drug abuse,During or within 14 days of MAO inhibitor use,Glaucoma
Avoid high-fat meals as they may delay absorption and alter peak concentration. Grapefruit and grapefruit juice may increase methylphenidate levels and should be avoided. Acidic foods (e.g., citrus fruits, colas) can affect drug absorption; maintain a consistent dietary pattern. Alcohol may cause dose dumping and should be avoided.
Avoid high-fat meals as they delay absorption; avoid acidic foods (e.g., citrus) and vitamin C supplements within 1 hour of dosing as they decrease absorption; limit caffeine and other stimulants to avoid additive cardiovascular effects.
Pregnancy Category C. First trimester: Possible increased risk of cardiovascular malformations and oral clefts from methylphenidate exposure; however, absolute risk remains low. Second and third trimesters: Risk of preterm birth, low birth weight, and neonatal withdrawal syndrome (including irritability, dysphoria, and poor feeding).
Pregnancy category C. First trimester: No well-controlled studies, but potential for congenital malformations not definitively established. Second and third trimesters: Increased risk of premature delivery, low birth weight, and neonatal withdrawal symptoms (e.g., dysphoria, agitation, lassitude). Chronic use may lead to neonatal toxicity.
Limited data. Methylphenidate is excreted into breast milk. M/P ratio not established. Infant relative dose <1% of maternal weight-adjusted dose. Monitor infant for agitation, insomnia, and poor weight gain. Avoid use in breastfeeding unless clearly necessary.
Excreted in breast milk. M/P ratio unknown. Potential for stimulant effects in infant (e.g., irritability, poor feeding, insomnia). Caution advised; consider alternative feeding methods.
Physiologic changes in pregnancy (increased plasma volume, renal clearance, and hepatic metabolism) may reduce methylphenidate levels. Consider increasing dose based on clinical response and tolerability, with gradual titration. Monitor for reduced efficacy in second and third trimesters. Use lowest effective dose.
No established dosing guidelines. Due to increased plasma volume and clearance, dose may need titration to clinical effect, but avoid supratherapeutic doses. Use lowest effective dose.
QUILLICHEW ER is an extended-release formulation of methylphenidate, a CNS stimulant, indicated for ADHD. Chewing or crushing the tablet destroys the extended-release mechanism, risking dose dumping. The tablet shell may appear in stool but is not medically significant. Monitor for growth suppression in children, weight loss, and potential for abuse. Avoid use in patients with glaucoma, motor tics, or family history of Tourette's syndrome. Use caution in patients with hypertension, tachycardia, or pre-existing psychiatric disorders like bipolar disorder or psychosis. Assess for potential drug interactions, particularly with MAOIs, anticoagulants (may decrease effect), and vasopressors.
For ADHD: start low, go slow; monitor weight and height in children; avoid late doses to prevent insomnia; check for abuse/diversion; screen for bipolar disorder and hypertension; consider urine drug screen before prescribing; avoid MAOIs within 14 days; use with caution in seizure disorders and glaucoma.
Take exactly as prescribed. Do not chew, crush, or split the tablet; swallow whole with liquid.,The tablet shell may appear in your stool, but the medication is absorbed; this is normal.,Do not take in the evening to prevent insomnia. Take in the morning with or without food.,Avoid alcohol while taking this medication; alcohol can affect the extended-release properties.,Common side effects include decreased appetite, trouble sleeping, dry mouth, and headache.,Report any chest pain, shortness of breath, fainting, or severe dizziness immediately.,Store at room temperature, protect from moisture, and keep out of reach of children.,Your doctor will monitor your blood pressure, heart rate, and weight regularly.,Do not stop abruptly; tapering may be needed to avoid withdrawal or rebound depression.
Take exactly as prescribed; do not crush or chew capsules.,Take the first dose upon waking; avoid afternoon/evening doses.,May cause insomnia, loss of appetite, or nervousness.,Do not drink alcohol while taking this medication.,Report chest pain, palpitations, shortness of breath, or mood changes.,Store securely; do not share medication with others.,Regular blood pressure and heart rate monitoring is necessary.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about QUILLICHEW ER vs ADDERALL 30, answered by our medical review team.
QUILLICHEW ER is a CNS Stimulant that works by Quillichew ER contains methylphenidate, a central nervous system (CNS) stimulant. The mechanism of action in ADHD is not fully understood, but it is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their availability in the extraneuronal space.. ADDERALL 30 is a CNS Stimulant that works by Adderall contains mixed amphetamine salts that increase synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and promoting release from presynaptic terminals.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between QUILLICHEW ER and ADDERALL 30 depend on the specific clinical indication. These are both CNS Stimulant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of QUILLICHEW ER is: Initial 20 mg orally once daily, titrate by 10 mg weekly to maximum 60 mg/day (methylphenidate component).. The standard adult dose of ADDERALL 30 is: Initial: 5 mg orally once or twice daily; increase by 5 mg increments weekly; usual maintenance: 20-30 mg daily in divided doses; maximum: 40 mg/day. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between QUILLICHEW ER and ADDERALL 30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. QUILLICHEW ER is classified as Category C. Pregnancy Category C. First trimester: Possible increased risk of cardiovascular malformations and oral clefts from methylphenidate exposure; however, absolute risk remains low. Se. ADDERALL 30 is classified as Category C. Pregnancy category C. First trimester: No well-controlled studies, but potential for congenital malformations not definitively established. Second and third trimesters: Increased r. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.